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A B S T R A C T
Loss of control over voiding following spinal cord injury (SCI) impacts autonomy, participation and dignity, and
can cause life-threatening complications. The importance of SCI bowel and bladder dysfunction warrants sig-
niﬁcantly more attention from researchers in the ﬁeld. To address this gap, key SCI clinicians, researchers,
government and private funding organizations met to share knowledge and examine emerging approaches. This
report reviews recommendations from this eﬀort to identify and prioritize near-term treatment, investigational
and translational approaches to addressing the pressing needs of people with SCI.
1. Introduction
Restoring bowel and bladder function following spinal cord injury
(SCI) is a top consumer and research priority (Anderson, 2004; Ditunno
et al., 2008; Liu et al., 2009; Braaf et al., 2017). Unfortunately, current
levels of research activity and emerging translational approaches do not
reﬂect this importance. The inability to control voiding is a persistent
problem for persons with SCI that reduces participation in activities and
deprives them of privacy and dignity. Because of the clear impact bowel
and bladder dysfunction has on the quality of life of these individuals,
the Craig H. Neilsen Foundation conducted a workshop to identify,
target and accelerate research areas ready for translation. This report
provides an overview of recommendations developed during the
workshop, reviews current eﬀorts that arose from the workshop, and
provides descriptions of activities needed from the larger community to
advance promising strategies for bowel and bladder management after
SCI.
Experts in SCI urogenital research, physiology, autonomic function,
biomedical engineering, clinical care, and patient advocacy formed an
advisory committee to assist in developing the workshop agenda, par-
ticipant list and plans to disseminate workshop outcomes (Appendix 1).
The event was held March 3–4, 2017 in Washington, D.C. with three
main goals: identify the most promising approaches for which a 10-year
translational timeline would be considered both reasonable and
achievable; bring together researchers and clinicians to exchange in-
formation and increase communication and cooperation between them;
and build collaborations between leaders in medical, industrial, patient
advocacy, research, regulatory and funding organizations to accelerate
future approaches that provide more eﬀective treatment options.
Participants worked in small groups on structured roadmap building
activities to develop a list of focus areas. First, clinicians, consumer
representatives and industry representatives shared their research and
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experience to present the issues. Next, breakout groups shared addi-
tional insight, deliberated and prioritized issues into a list of problems
to solve. Throughout the workshop, focus was directed to the most
pressing constituent needs and identiﬁcation of opportunities to address
these needs. Small group recommendations were presented and dis-
cussed at the end of the two-day event. Interestingly, 5 out of the 6
small groups identiﬁed the same ﬁrst step for improving bowel and
bladder management. This recommendation, to identify and dis-
seminate treatment guidelines, was described as readily achievable.
As the main outcome of the workshop, these working groups de-
veloped collective recommendations that were organized into ﬁve
thematic areas. They range from steps described as immediately
achievable to areas that require further investigation and longer de-
velopment timelines. Recommendations also span broad but distinct
skill areas such as communication and biomedical engineering.




Update, disseminate, and provide guidance
to consumers and clinicians on current
therapeutic approaches. Create a consumer
proﬁle to characterize needs, including
lifestyle and poly-pharmacy.
Bowel physiology Prioritize eﬀorts to understand
gastrointestinal physiology to elucidate the
eﬀects of SCI and therapeutic interventions
on bowel function, including its relationship
to the urinary system.
Sensory awareness Identify technology and approaches that
can measure key indicators of the need to
void or system dysfunction and thereby
enable patient awareness in daily activities
and potential for improved diagnosis.
Neuromodulation Use existing systems or create novel
technologies that can replace or restore




Quantify evidence and build an
understanding of how seemingly unrelated
approaches (e.g., exoskeletons, treadmills,
overground walking, and other therapies)
have a positive eﬀect on bowel and bladder
function.
2.1. The problem and how it is managed
Neurogenic bladder is a broad term for bladder and sphincter dys-
function due to a neurological disease or condition. In SCI, urologic
clinical manifestations depend on the level and extent of the injury
(Wein and Dmochowski, 2011). A complete lesion above the sacral
spinal cord results in detrusor overactivity, smooth muscle sphincter
dyssynergia and striated muscle sphincter dyssynergia. Striated
sphincter dyssynergia will result in an obstruction with high detrusor
pressure and poor bladder emptying. Sacral SCI will usually demon-
strate bladder atony or areﬂexia with normal or high bladder com-
pliance (elasticity). Decreased compliance may develop, which can lead
to hydronephrosis and irreversible kidney damage.
In practice, SCI neurogenic bladder dysfunction's presentation is as
varied as the individuals aﬀected with SCI, almost all of whom face a
struggle to manage this condition on a day-to-day basis. A key issue was
described as the inability, for those with SCI, to detect rising bladder
pressure or bladder fullness in a “closed loop system.” Additionally, the
level of injury was also discussed in its relationship to symptomatic
presentation and intervention targets. ‘The Functional System’ de-
scribes the bladder dysfunction in terms of occurring in the ﬁlling/
storage or emptying/voiding phase of micturition (Wein and Barrett,
1988). This classiﬁcation, generally divided into “Failure to Store” and
“Failure to Empty,” has been expanded to include speciﬁc urodynamic
ﬁndings based upon the activity of the detrusor and sphincter outlet
noted as either hyperreﬂexic, normoreﬂexic, or areﬂexic (Krane and
Siroky, 1984). These three classiﬁcations deﬁne the main therapeutic
targets: failure of storage (incontinence), failure to empty or a combi-
nation of the two. Each condition could be due to dysfunction of the
bladder, the sphincter, or both.
Urological systems are fairly well described in the scientiﬁc litera-
ture (de Groat et al., 2015), which enabled robust discussions regarding
the appropriateness and eﬀectiveness of long-term treatment options.
Clinicians described their standard practices for developing a bladder
management strategy for consumers with SCI, which they admitted rely
heavily on where they conducted their residency and what options they
had experience with. Non-electrical devices comprise the majority of
supportive technology used in standard practice. These devices are ei-
ther catheters (intermittent and indwelling (e.g., Foley)) or stents
(prostatic and urethral). Surgical approaches were described as an op-
tion recommended only when patients expressed deep dissatisfaction
with their current management approach. Surgical options include
sphincterotomy, bladder enlargement (i.e., augmentation cystoplasty),
urinary diversion or cystectomy to by-pass the bladder and lumbar
sacral rerouting. Botulinum toxin injections are often used to relax the
bladder and this option is growing in popularity due to the reversible
nature of this approach. Workshop participants also received an over-
view of emerging, and hence, less commonly utilized electrical ap-
proaches to restore bladder function. The biological targets include
stimulation at the level of the spinal cord, spinal nerve roots, peripheral
nerves or muscles of the bladder wall and sphincter. These targets are
reached via a multitude of simulation modalities, including pharma-
cological, ultrasonic, magnetic, or electrical delivered through devices
(i.e., surface and implanted) (Gaunt and Prochazka, 2006) or pharma-
cological routes of administration (e.g., oral, rectal). Hence, a wide
range of options need to be considered, in relation to both clinical ef-
fectiveness and patient preference.
Neurogenic bowel is a colonic dysfunction resulting from a lack of
central nervous control of the gastrointestinal tract (Krassioukov et al.,
2010a, 2010b). This condition is commonly observed in individuals
with SCI and clinically presents as two distinct patterns of bowel dys-
function; injury above the conus medullaris results in upper motor
neuron bowel syndrome and injury at the conus medullaris and cauda
equina results in lower motor neuron bowel syndrome (Krassioukov
et al., 2010a, 2010b). Upper motor neuron bowel syndrome is char-
acterized by high pressure and lost coordination of rectal contractions
that result in a failure to relax the anal sphincter. Lower motor neuron
bowel syndrome is characterized by areﬂexic rectum and low anal
sphincter pressure. Both of these conditions have been shown to reduce
transit through the colon. Similar to bladder, failure to store (fecal in-
continence) and empty could be due to either/both bowel or sphincter
dysfunction. Neurogenic bowel dysfunction is a major physical and
psychosocial problem for individuals with SCI, as changes in bowel
motility and sphincter control are coupled with impaired mobility and
loss of hand dexterity. The clinical management approach to bowel
dysfunction after SCI is overwhelmingly the use of digital stimulation
(Stiens et al., 1997; Correa and Rotter, 2000; Yim et al., 2001;
Krassioukov et al., 2010a, 2010b). This was described as the routine
practice in therapy and, in many centers, demonstrated success is re-
quired prior to hospital release. trans-Anal irrigation is utilized more
commonly in Europe than in the US, and is mainly used when other
approaches fail (Emmanuel, et al., 2013). The primary goals of therapy
are to reduce the amount of time spent on defecation, minimize fecal
incontinence and reduce the impact of bowel management on quality of
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life (Christensen and Krogh, 2010). Pulse irrigation is eﬀective, but
impractical due to the bulky machinery that is needed. Initially, un-
manageable fecal incontinence is treated by use of absorbent under-
garments, anal plugs, or rectal catheters such as ProCon2® devices
(Duelund-Jakobsen et al., 2016). Surgery, such as bowel diversion (i.e.,
latissimus dorsi myorrhaphy) or sphincter augmentation, is used as a
last resort due to poor long-term outcomes (Lehto et al., 2013; Bravo
Gutierrez et al., 2004). Emerging electrical approaches include sacral
nerve stimulation, however, participants expressed doubt regarding the
value and eﬀectiveness of this approach as reported in previous studies
(Binnie et al., 1991). Overall, it was noted that much more scientiﬁc
study of bowel physiology is needed to target next-generation therapy
development (Duelund-Jakobsen et al., 2016 for review). There was a
discussion speciﬁcally about need to develop better measures of phy-
siology (in spinally injured as well as other individuals) in addition to a
need for better understanding of the relationship between abnormal gut
physiology and symptoms.
3. Expanded recommendations
3.1. Education and clinical care standards
Clinicians described the paucity of current guideline documents and
the challenges they face when their patients are either uninformed or
misinformed. Consumer representatives echoed this concern and con-
ﬁrmed that the majority of individuals with SCI turn to online resources
as a ﬁrst step (Matter et al., 2009), which can yield inconsistent and
questionable information. Although clinicians and consumers harbor
the same concerns, they also described the tendency to talk past each
other. Clinicians prioritize health and resolution of physical dysfunction
whereas consumers prioritize convenience, reliability, ease of use, cost
and practicality. Physician resources for SCI bowel and bladder dys-
function are provided through multiple sources. The Paralyzed Veterans
of America (PVA) and associated Consortium for Spinal Cord Medicine
develop some of the most well-known clinical practice guidelines (CPG)
for consumers and health-care providers in the U.S. [http://www.pva.
org/publications/clinical-practice-guidelines]. Downloadable and
freely available, they contain evidence-based recommendations and
guidance to address common concerns in SCI practice. However, the
PVA bladder and bowel guidelines were originally published in 2006
and 1998, respectively, and clearly need to be updated (Consortium for
Spinal Cord Medicine, 2006; Consortium for Spinal Cord Medicine,
1998). In Canada, the Rick Hansen Institute (RHI) has developed a
broad resource for clinicians worldwide, Spinal Cord Injury Research
Evidence (SCIRE), that includes treatment approaches, instructional
videos and toolkits on many topics. The bladder and bowel guidelines
were published in 2014 (Coggrave et al., 2014; Hsieh et al., 2014), and
an updated version is being released in sections, starting in January
2017 [https://scireproject.com]. The existence of these and other re-
sources and guidelines, developed independently, led participants to
prioritize the need for coordinated communication, awareness, updates,
consumer access and clinician usability. They recommended the fol-
lowing next steps.
Recommended community actions
1. Conduct a systematic review of available resources and best prac-
tices.
2. Collaborate domestically and internationally to centralize materials.
3. Update resources and incorporate diet, nutrition, and sexual func-
tion.
4. Develop versions for patient (description) and clinician (technique).
5. Standardize measures for future studies where possible and utilize
common data elements.
6. Develop a consumer proﬁle and incorporate patient priorities and
preferences in treatment pyramid and decision tree.
7. Ensure care standards are easy to use, downloadable and freely-
available through traditional and modern sources such as social
media and peer support sites.
8. Utilize advocacy/organizational groups for wide dissemination.
Further discussion topics included the potential beneﬁts of ex-
panding telemedicine and development of a support organization to
bring groups together for research/information standardization every
few years.
As an initial step toward centralization and dissemination of current
materials within the U.S., a few participants recommended working
with the large longitudinal database of the SCI Model Systems Centers.
These Centers, funded through 5-year awards from the National
Institute on Disability, Independent Living, and Rehabilitation Research
(NIDILRR), are recognized for their leadership in medical research and
patient care. Other large data resources include the Rick Hansen SCI
Registry (RHSCIR) (Fehlings et al., 2017), and a new eﬀort to co-
ordinate data sharing in SCI research in a “FAIR” Findable, Accessible,
Interoperable and Reusable manner (Callahan, et al., 2017). Utilization
of common data elements for clinical documentation as well as research
(Biering-Sørensen et al., 2015) would also support eﬀorts in another
important thematic area, bowel physiology.
3.2. Bowel physiology
The workshop agenda was designed such that a review of bowel and
bladder systems would inform breakout groups in identifying patho-
physiological intervention targets. Compared to urological systems,
bowel physiology and the mechanisms of dysfunction after SCI are not
well understood. Although bowel and bladder are related systems, the
imbalance of knowledge between them became clearly apparent. The
ability of able-bodied individuals to selectively evacuate material based
on its structure (e.g., solid, liquid, gas) underscores the complexity of
the healthy enteric nervous system. Many argued that what is known
about colonic transit, rectal compliance and anal reﬂexes provide only
the most basic information. The lack of information on mechanisms of
gastrointestinal dysfunction after SCI hampers the ability to identify
surgical, pharmacological, and neuromodulatory targets to manage or
reverse people's symptoms. Although there is much to be learned about
bowel pathophysiology following SCI, clinicians and consumers were
fairly well aligned in describing available treatment approaches: Diet,
exercise and managing poly-pharmacy are the most common front-line
approaches. Clothing and schedule adjustments are often considered
along with practicality and lifestyle. Devices such as trans-anal irriga-
tion systems, neuromodulation and surgical interventions are reserved
for treatment-resistant cases when risk of the intervention is out-
weighed by lifestyle impact due to the declining functional status.
Although doctor/patient communication on bowel dysfunction was
described as well-aligned, data presented from a recent sociological
research study on challenges and life with bowel dysfunction high-
lighted the urgency of addressing several issues. These topics regarding
bowel dysfunction in general, and relating to SCI speciﬁcally, were
documented in an ethnographic study with a quantitative part, invol-
ving 74 people with SCI, of a total of 361 respondents with bowel
dysfunction of diverse origin (Coloplast Market Study [dataset], 2017):
Bowel dysfunction in SCI and other medical conditions
• Bowel problems are usually treated through symptom management
over years (and often decades) as the systemic dysfunction continues
unresolved.
• About half (54%) of people with bowel problems in this sample
sought medical attention within a month of symptom onset, but
11% waited 6months or more and some may not have sought at-
tention until hospitalized. The proportions were similar in those
individuals in the sample with SCI as the underlying cause of their
bowel problems.
• Social media, websites and peer support groups are the main source
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of information for those with bowel dysfunction (66% collectively),
about which, physicians express concern regarding misinformation
in online sources. A healthcare professional is the main source of
information about bowel problems for 26% of the respondents
across patient groups, including SCI.
• Bowel and bladder dysfunction comorbidity is high; urinary incon-
tinence and urinary tract infections are the most common co-
morbidities. For 78% of the responding SCI participants, bowel
problems were considered equally or more important than urinary
incontinence.
• Bowel dysfunction seems to coexist with mental health problems
such as depression and anxiety. Although 71% of responding phy-
sicians and nurses treating bowel dysfunction are acutely aware of
these relationships, treatment referrals are seldom provided for this
cause.
• Bowel incontinence is an important and persistent problem that can
lead to hospitalizations. Fifty-six percent of the responding SCI pa-
tients aﬃrmed having been hospitalized at least once due to a bowel
problem in the previous 12months; 68% of those were emergency
admissions.
• Fifty-ﬁve percent of individuals with SCI who responded said their
bowel problems have caused them to avoid activities or cancel social
engagements in the past year.
• A signiﬁcant number of SCI respondents said they had tried over the
counter medication and/or natural remedies for their bowel pro-
blems without consulting with a healthcare professional (45% and
37%, respectively).
• Among the many individuals with SCI who experienced a change in
their bowel health in the previous year, most (63%) described it as
‘getting worse.’
• Most clinicians are unaware or avoid use of tools such as the neu-
rogenic bowel disorder score (Krogh et al., 2006) or the 2013 pyr-
amid of bowel dysfunction (Emmanuel, et al., 2013) and therefore
are unsure how to escalate interventional strategies. Even if these
tools were used more commonly, many argue that more metrics to
accurately assess bowel problems are needed.
Although these data indicate signiﬁcant challenges related to bowel
dysfunction care, participants discussed several eﬀective treatments
that do exist and worked to identify additional opportunities.
Evacuation, constipation and gut motility can be addressed through
pharmacological approaches, including laxatives and serotonin agonists
(Krassioukov et al., 2010a, 2010b; Singal et al., 2006). Neostigmine
eﬀectively treats acute colonic pseudo-obstruction, Cisapride increases
motility in the upper intestinal tract, however, cardio-vascular com-
plication risk must be considered and Prucalopride has shown good
results in handling chronic constipation (Geders et al., 1995). Physical
therapy, neuromodulation or surgical approaches for fecal incontinence
have shown some success, but participant opinions varied widely and
the prevalence of use of these approaches diﬀered across countries and
the institutions therein. It was agreed that no approach has demon-
strated reliability in addressing fecal incontinence. Workshop partici-
pants could identify few researchers actively addressing these issues or
speciﬁc approaches under development that show particular promise.
There was strong consensus that the ﬁeld needs more basic information
to generate priority targets. It also was noted that growing research
regarding the microbiome warrants further development in this area
(Gungor et al., 2016). In summary, the following recommendations
were put forward to improve bowel care after SCI:
Recommended community actions
• Provide gastroenterologists, colorectal surgeons, general practi-
tioners, and neurologists who treat bowel dysfunction, tools and
referral resources to identify and address psychological conditions
such as anxiety and depression.
• Develop diagnostic tools and a clear medical referral pathway for
treatment that accounts for level of injury, completeness, time
postinjury, age and gender. Physiological phenotypes are needed for
bowel dysfunction based on level and severity of injury, for ex-
ample, to enable clinicians to determine high/low compliance and
with/without anal dyssynergia.
• Develop and make available resources for patients to address po-
tential misinformation as well as encourage individuals to seek
proper treatment from the medical professionals best equipped to
help them.
• Conduct research to understand bowel function, identify potential
intervention targets and clarify the close relationship with bladder
system dysfunctions.
Many of the breakout groups suggested that inroads in bowel
management would likely have a positive impact on bladder systems
due to potential interrelationships between the two systems. The three
remaining thematic areas support this assertion; sensory awareness,
neuromodulation, and secondary eﬀects of other rehabilitation, activity
and exercise interventions, all of which apply equally to both bowel and
bladder.
3.3. Sensory awareness
Participants in all working groups were asked to identify emerging
approaches that have translation potential within the decade. There
was agreement early in the discussion that many serious health issues
and potential incontinence “accidents” could be avoided if sensory in-
formation, such as bladder fullness, pain due to impaction or urinary
tract infection (UTI) was available. For example, it is well documented
that autonomic dysreﬂexia can be triggered by activation of the sensory
aﬀerents due to an over-ﬁlled bladder or colon, routine bladder emp-
tying, digital stimulation or the process of manual evacuation (Faaborg
et al., 2014; Lee et al., 2017; Vaidyanathan et al., 2017, 2018). Dys-
function in sensory feedback varies based on each injury; while some
individuals with SCI retain some sensation, others have little or no
sensory warning before a bowel or bladder movement. First line man-
agement approaches described previously, such as digital stimulation
and catheter use, are most eﬀective when sensory awareness is present.
Individuals with reduced or absent sensory awareness must rely on
scheduled bowel and bladder care and are more prone to accidents or
serious complications.
Workshop participants argue that sensory awareness as a substitute
to normal sensation would signiﬁcantly reduce and potentially prevent
accidents and medical consequences. Even without improved bladder
and/or bowel evacuation approaches, an alert that bowel/bladder
emptying needs are approaching a critical point would be an important
advancement. Participant recommendations focused on developing di-
agnostic and monitoring systems that provide notiﬁcation of the need to
evacuate (Craggs et al., 2006). Short and long-term approaches for the
development of surrogate signals to monitor key parameters (e.g., dis-
tention, solid vs. gaseous pressure) were identiﬁed. Monitors could be
developed for biological targets such as the bladder wall and sphincters
as well as non-biological targets such as indwelling and intermittent
catheters. Devices will require specialized sensor development because
as one participant noted, catheter-based pressure systems used in
bladder have been proven unreliable for bowel. The need to focus on
devices that treat both failure to empty and failure to store were also
described by several breakout groups.
Recommended community actions.
Short term
• Develop a pressure monitor for indwelling bladder catheters and
consider application of valved catheters, where this would increase
convenience.
Long term
• Develop wireless volume and pressure monitoring for bladder to
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inform a person in a discrete manner when catheterization is
needed. This type of novel device would enable more independence
to travel, work, and participate in social activities without worry.
• Similarly, development of a continual monitoring device to give
patients continuous health information on state of their bowel:
distension, motility, volume, strain.
• Promising implant locations for bowel sensor(s) were identiﬁed as
being submucosal in the rectum and/or sigmoid colon (Trivedi
et al., 2016).
Monitoring devices could be either permanent or built to function
for a month or so to give consumers a better sense of what their sur-
rogate sensations “mean.” Workshop participants argue that in the fu-
ture data from these devices would inform clinicians for diagnostic and
therapeutic purposes and provide consumers with more independence.
Technology development should be geared toward dynamic monitoring
of combined measures, such as pressure and volume in distal bowel, as
current approaches such as anal manometry provide only static mea-
surements. Further beneﬁts of chronic monitoring are tracking of
change over time, allowing clinicians to monitor or ﬁne tune treatments
or developing new therapies. Participants discussed common clinical
observations where management programs remain eﬀective for decades
then unexpectedly fail. The ability to track changes in pressure, dis-
tention and fullness over time would provide insight into the source of
these failures, which are currently hypothesized to be due to age or
scarring. In the absence of better clinical data, maintenance of eﬀective
bowel and bladder management strategies will remain diﬃcult. Some
of these recommended long-term approaches were known to currently
be in development, such as indwelling pressure measurement devices,
but others, including molecular sensing for UTI and ultrasonic detection
of fullness, were in the early stages of idea generation. A critical ﬁrst
step is to exploit an animal model to help develop such technology and
initiate testing of its safety and utility.
In summary, restoring sensory awareness was recognized as a highly
important, yet underdeveloped emerging approach that holds great
potential. Since the workshop was held, one company, Spinal
Singularity, began clinical safety trials on a bladder device called the
Connected Catheter, which has an imbedded sensor and wireless alert
system (https://clinicaltrials.gov/ct2/show/NCT03405285). Although
this company was not part of our workshop, their eﬀort to develop
technology in line with this consensus recommendation seems to con-
ﬁrm the importance. Once reliable sensory awareness is established and
determined safe for people with SCI, use as a clinical diagnostic tool or
to provide feedback control of other emerging approaches will also be
enabled. Participants formed a sensation working group, with the goal
of identifying available and/or emerging technology that could be le-
veraged within 10 years. Detailing the steps the ﬁeld could take next on
priority areas will involve identifying the opportunities and barriers
that exist in accomplishing these goals and dissemination to the larger
community. As this group evolves and progresses, they will add needed
expertise and foster a relationship with other working groups. Indeed,
in addition to providing the user with important feedback, sensors
would enable closed-loop neuromodulation systems.
3.4. Neuromodulation
Control of nervous system function through electrical, chemical or
other stimulus delivery methods has experienced signiﬁcant advance-
ment in scientiﬁc research and clinical practice (McGee et al., 2015).
Although the neuromodulation sector for incontinence is projected to
grow 13% annually (Cavuoto and French, 2018), additional rando-
mized control trials are necessary to determine the eﬃcacy of these
approaches in SCI (Kessler et al., 2010). Electrical stimulation targets to
restore bladder function include the nerves of the sacrum such as the
pudendal and tibial nerves or the sacral roots. Targeting these nerves
with electrical, optogenetic, ultrasonic, or pharmacological approaches
can range from precise (e.g., microscale, cellular speciﬁc) to systemic
delivery (i.e., drugs). There are many types of devices that provide
targeted stimulation, such as highly investigational micro- and na-
noscale technologies created in laboratories across the globe (e.g., Seo
et al., 2016) and clinically-used milli-scale devices from Medtronic,
Boston Scientiﬁc, St. Jude and others (Kumsa et al., 2018). Although
devices designed speciﬁcally for those with SCI are urgently needed,
while focusing on a 10-year timeframe, participants recommended
avoiding an exclusive focus on developing new technology for several
reasons. First, they agreed there were many devices already on the
market or in advanced stages of development that might be applied to
treat bladder and bowel dysfunction. Many advances in technology are
being made through recent initiatives such as NIH's SPARC and DAR-
PA's ElectRx programs, and leveraging technology should be possible.
Several groups also expressed concern over translation of wholly new
approaches within a reasonable timeframe due to the long-development
timeline for regulatory approval of new devices. Instead, a focus on
developing neuromodulation approaches that leverage existing and
emerging technology was recommended.
Several decades have passed since the emergence of sacral anterior
root stimulation using the Finetech-Brindley bladder system (Vocare).
This device provides on-demand urination and reduces residual urine
volume in persons with SCI who have clinically complete spinal cord
lesions with intact parasympathetic innervation of the bladder. This
device showed positive results in over 2000 users worldwide (Gaunt
and Prochazka, 2006), many of whom reported experiencing beneﬁts to
defecation, as well. Workshop participants' views and experience re-
garding consumer acceptance of this approach varied. Many argued
that those who have received the surgically implanted device are the
strongest advocates; they also described potential bias against this ap-
proach as accounting for decreased use. Others noted that many po-
tential users are intolerant to the thought of elective posterior rhi-
zotomy (severing intact sensory nerves) and cited individual cases with
disappointing results. The rhizotomy procedure is required to treat
neurogenic detrusor overactivity (incontinence) and bladder sphincter
dyssynergia (Kirkham et al., 2002), as the stimulator only addresses
bladder emptying. It was clear that there is little consensus in re-
commending this approach, and further systematic analysis of user
outcomes would be beneﬁcial.
Examples of other electrical stimulation approaches that avoid the
need for a posterior rihzotomy were discussed including sacral neuro-
modulation (Wöllner et al., 2015; Lombardi et al., 2014), epidural
spinal cord stimulation (Pettigrew et al., 2017), pudendal nerve sti-
mulation (Horvath et al., 2010; Yoo et al., 2011), and tibial nerve sti-
mulation (Chen et al., 2015). However, well-designed, randomized and
controlled studies are required to evaluate these emerging approaches
(Ren et al., 2016). The Wöllner and Lombardi studies speciﬁcally de-
scribe recommendations to avoid use in incomplete SCI with neuro-
genic detrusor overactivity (NDO) or chronic retention. It was also
noted that sacral neuromodulation cannot reliably suppress NDO and
should only be considered as a treatment option for symptomatic
neurogenic lower urinary tract dysfunction in carefully selected sce-
narios where there is low risk for upper urinary tract damage. kHz-
frequency biphasic stimulation can block conduction in the pudendal
nerve and may be chronically reversible and repeatable (Kilgore and
Bhadra, 2014 for review). The beneﬁts of neuromodulation to keep
bladder pressures low through relaxation of the detrusor muscle was
acknowledged, however, opinions varied regarding what approach and
level of invasiveness would be required to achieve this, as well as other,
similar goals. Participants identiﬁed numerous opportunities in neuro-
modulation for bowel and bladder control, related to identiﬁcation and
focus on speciﬁc biological targets, and as well as enhancing emerging
stimulation modalities. Clinical use of kHz peripheral nerve block has
been approved by the FDA and studied in obesity (Ikramuddin et al.,
2014) which may support its translation in other therapeutic condi-
tions. There was broad agreement that pursuing neuromodulation
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strategies has strong potential; there was less agreement about which
speciﬁc approach holds the most promise. There was consensus, how-
ever, that leveraging existing technologies would increase the like-
lihood of translating approaches within the decade.
Recommended community actions
• Enhance existing sacral anterior root electrical stimulation systems
to maintain eﬃcacy while eliminating the need for a rhizotomy.
• Focus eﬀorts on repurposing existing neuromodulatory drugs and
devices for use in SCI bowel and bladder management, with con-
sumer preference guiding development.
• Develop staged translational approaches beginning with surface
stimulation such as targeting the genital branches of the pudendal
nerve for bladder control and possibly bowel continence.
• Perform mechanistic studies of sacral neuromodulation to support
the development of safe and eﬀective stimulation approaches for
bowel and bladder management.
• Develop reliable selection criteria and incorporate quantiﬁable
measurement criteria to assess eﬃcacy.
• Identify early intervention strategies to prevent the development of
detrusor sphincter dyssynergia (Sievert et al., 2010) and other un-
favorable symptoms.
• Incorporate biofeedback to enhance control in those with in-
complete lesions.
• Explore a combination of therapies (e.g., electrical stimulation and
drugs).
• Leverage known recto-colonic reﬂex functions to replace current
approaches such digital stimulation.
It became apparent during discussions that awareness of existing
and emerging technologies varied greatly. Researcher scientists shared
knowledge of novel electrical, optogenetic and ultrasonic approaches
whereas clinicians provided insight into surgical, pharmacology and
transanal irrigation beneﬁts and drawbacks. Potential options to com-
bine known approaches (e.g., targeted drug delivery via transanal ir-
rigation) or build upon emerging technology (e.g., optogenetic stimu-
lation or inhibition) were evaluated in terms of their likely translational
timeline. One participant described the potential to accelerate this
timeline through the development of public/private partnerships
[http://mdic.org/]. Similarly, industry representatives described op-
portunities and experience with collaborative research and develop-
ment eﬀorts.
In an eﬀort to consider both emerging and existing technology, a
Neuromodulation working group was created to identify technology,
either available or emerging, which could be leveraged within 10 years,
and the steps needed to make meaningful progress. This will again in-
volve identifying key opportunities and barriers and informing the ﬁeld
on these recommendations through a publication. In addition to high-
tech research and development in neurotechnology, participants iden-
tiﬁed several clinical trials in SCI that reported improvements in bowel
and bladder function as a secondary or unexpected outcome.
Understanding and capturing such data emerged as a high priority
during the workshop discussion.
3.5. Rehabilitation, activity and exercise
Current clinical trials in SCI that listed bowel and/or bladder as a
primary or secondary outcome measure were reviewed during the
workshop. In most, bladder or bowel outcomes were secondary to the
trial focus on areas such as locomotor function, pain and respiration.
Interventions included rehabilitation, cell transplants, scaﬀolds, elec-
trical or magnetic stimulation, activity-based training, or various
combinations thereof. Many workshop participants described anecdotal
ﬁndings from trials and case studies that underscore the broad impact
physical movement has on individuals with SCI. There was consensus
that such observations are intriguing, but not rigorous enough to aﬀect
implementation. These data are beginning to be collected and assessed
(Hubscher et al., 2018), but a more comprehensive approach is needed
to learn from and leverage any potential beneﬁts. Participants noted
that data collection approaches varied in the studies reviewed, with no
single bowel or bladder measurement technique or regimen common to
all. Outcomes tools have been developed to address concerns of com-
parability between studies, including the SCIRE project [https://
scireproject.com/], NIH's common data elements [https://www.nlm.
nih.gov/cde/] International SCI data sets [http://www.iscos.org.uk/
international-sci-data-sets], and The SCI-Quality of Life measurement
system (Tulsky and Kisala, 2015), but most published studies have yet
to incorporate or report on standardized outcomes. The need to better
capture and quantify improvements in bowel and bladder function was
apparent throughout the workshop discussion. A summary of areas that
should be addressed is provided below.
Recommended community actions
• Identify core QOL measures for SCI in bladder and bowel based on
consumer preference for meaningful improvement.
• Encourage use of bowel and bladder outcome measures that can
become standards in studies where the intervention target is not
speciﬁc to bowel and bladder management.
• Deﬁne types of data to collect and speciﬁc methods or biomarkers
(e.g., UTI incidence with speciﬁc deﬁnition of what constitutes a UTI
in individuals with SCI.) for all ongoing SCI trials.
• Use health economics to deﬁne important outcomes related to bowel
and bladder management to inform regulators and payers.
• Systematically encourage/expect capture and sharing of common
data elements consistently to enable meta-analyses.
These recommendations appear straightforward, yet require ex-
tensive collaboration to be successful. Participants emphasized that
variations in measurement approaches are necessary for both dys-
function-speciﬁc and trial-speciﬁc reasons, and the desire for consistent
measurement should not outweigh strong experimental design. Instead,
participants argued that if a key set of supplemental bowel and bladder
measures could be developed with a low data collection administrative
burden, researchers would likely embrace collection and reporting of
such outcomes. Participants concluded that this topic required addi-
tional consideration, so a third working group was convened to begin
developing this core list of bowel and bladder measurement tools. The
objective of this working group is to act as a collective voice to develop
and disseminate bowel and bladder measurement recommendations to
the larger community.
4. Discussion/summary
The inability to control voiding, particularly incontinence, is a
deeply personal topic. It reduces participation in public activities, de-
creases sexual conﬁdence, and is considered by many to be one of the
most debilitating aspects of life after SCI (Rubin et al., 2016). One
participant summarized the workshop with this simple message: “It's
about dignity.” Until quite recently, SCI researchers devoted little focus
to studies in bowel and bladder management, even though dysfunction
in these systems has serious medical complications and psychological
impact for those living with SCI. The Craig H. Neilsen Foundation
bowel and bladder workshop was designed as a ﬁrst step in addressing
this research gap. Discussions weighed strategies and options, set
priorities and outlined actions to advance promising approaches. It was
apparent that signiﬁcant actions remain to be undertaken in order to
achieve real change in the lives of those living with SCI. Three working
groups were formed to begin addressing the identiﬁed gaps, however,
real changes in foreseeable future require a larger community eﬀort.
Funders, industry, regulatory, and community groups must act within
their disciplines and build or join collaborative eﬀorts. Researchers and
clinicians need to continue to build momentum in these areas. The
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recommendations and subsequent activities described here, are pre-
sented to help the community move forward. In 2004 a seminal paper
was published describing research priorities according to those living
with SCI, and few changes in treatment have been made since then
(Anderson, 2004).
Consensus and momentum were developed during this workshop
that should result in tangible improvements in bowel and bladder
management after SCI. Participants noted that although addressing key
issues of reliable continence, voiding and access to current information
may require a decade for achievement, recommendations provided
herein can reasonably be accomplished within that time. Opportunities
identiﬁed span a spectrum of technical challenges from those con-
sidered low-hanging fruit (e.g., updated guidance) to more diﬃcult
engineering and basic science research. Similarly, they range in de-
velopment time from long-term solutions, which require additional
scientiﬁc exploration and identiﬁcation, to numerous readily achiev-
able goals such as updating CPGs, maximizing FAIR data usage, and
expanding telemedicine. Strategies also included prevention of known
progressive health-related issues such as DSD, bowel impaction and
UTIs and also highlighted the need to consider and incorporate user
lifestyle for optimal care. Workshop participants' contributions before,
during and after the meeting in the post-workshop working groups
described, have already moved us closer to achieving these goals. The
Neilsen Foundation has also committed to support, and thereby accel-
erate, the PVA's updating of the Bowel Management CPGs. Although the
accomplishments described are important, they are just a beginning. It
is hoped that others in the community will now join these eﬀorts.
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